QUEBEC CITY, February 07, 2025--(BUSINESS WIRE)--Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique ...
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to ...
Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to ...
QUEBEC CITY, February 07, 2025--(BUSINESS WIRE)--Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique ...
(1) Pr. Louis Flamand is a director on the board of directors of the Corporation Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative ...
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to ...
Their findings enhance our understanding of gene regulation during blastoid formation and ... New Drug Tested to Reduce Side Effect of 'Half-Matched' Stem Cell Transplants Dec. 5, 2024 — Stem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback